iiCON and the Liverpool School of Tropical Medicine: A partnership tackling emerging viral threats and neglected tropical diseases
A £2.7 million Translational Development Fund to support the development of new diagnostics and treatments.
Overview
The Translational Development Fund was launched in partnership with the Liverpool School of Tropical Medicine (LSTM) to support the development of diagnostics and treatments. We also joined the LSTM-led Infection Innovation Consortium (iiCON) to accelerate the discovery and development of new therapies and innovations.
About the Translational Development Fund
We are partnering with the Liverpool School of Tropical Medicine (LSTM) to launch a new £2.7 million Translational Development Fund. This fund will support the development of diagnostics and treatments to tackle emerging viral threats and neglected tropical diseases.
Who is the fund available to?
The fund will be available to all of LSTM’s partners, including research organisations in low-and-middle-income countries.
Infection Innovation Consortium (iiCON)
We have also joined the LSTM-led Infection Innovation Consortium (iiCON), alongside other core partners such as Unilever, Evotec, the Liverpool University Hospitals Foundation Trust, the University of Liverpool, and Infex Therapeutics. The aim of the £250 million programme is to accelerate the discovery and development of new therapies and innovations.
iiCON agreement
As part of this agreement, we have made our antibody humanisation platform available for iiCON and its partners to support the development of new potential treatments. The Translational Development Fund will also be available to iiCON and its collaborators.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Related stories
-
News releases
Promising results in clinical trial gives hope to patients with blood disorder
Read more: Promising results in clinical trial gives hope to patients with blood disorder -
News releases
3 steps LifeArc is taking to tackle antimicrobial resistance before it’s too late
Read more: 3 steps LifeArc is taking to tackle antimicrobial resistance before it’s too late -
News releases
£76M investment backing into potential MND treatment, underlines benefit of charity funding
Read more: £76M investment backing into potential MND treatment, underlines benefit of charity funding